An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial-Reference-Cited by-同舟云学术

An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

Published:2023-02 Issue:10375 Volume:401 Page:458-469
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Aygören-Pürsün Emel,Zanichelli Andrea,Cohn Danny M,Cancian Mauro,Hakl Roman,Kinaciyan Tamar,Magerl Markus,Martinez-Saguer Inmaculada,Stobiecki Marcin,Farkas Henriette,Kiani-Alikhan Sorena,Grivcheva-Panovska Vesna,Bernstein Jonathan A,Li H Henry,Longhurst Hilary J,Audhya Paul K,Smith Michael D,Yea Christopher M,Maetzel Andreas,Lee Daniel K,Feener Edward P,Gower Richard,Lumry William R,Banerji Aleena,Riedl Marc A,Maurer Marcus

Publisher

Elsevier BV

Subject

General Medicine

Reference39 articles.

1. Hereditary angioedema: new findings concerning symptoms, affected organs, and course;Bork;Am J Med,2006

2. Hereditary angioedema;Busse;N Engl J Med,2020

3. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy;Zanichelli;Orphanet J Rare Dis,2015

4. International consensus on hereditary and acquired angioedema;Lang;Ann Allergy Asthma Immunol,2012

5. Hereditary angioedema: epidemiology and burden of disease;Lumry;Allergy Asthma Proc,2020

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy inhibition mediated via an injectable and NO-releasing hydrogel for amplifying the antitumor efficacy of mild magnetic hyperthermia;Bioactive Materials;2024-09

2. Current and Emerging Therapeutics in Hereditary Angioedema;Immunology and Allergy Clinics of North America;2024-08

3. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks;New England Journal of Medicine;2024-07-04

4. New Therapies for Type 1 and Type 2 Hereditary Angioedema;New England Journal of Medicine;2024-07-04

5. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma;Neuroglia;2024-07-02